This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Erasca Inc. is a clinical-stage precision oncology company developing drugs to treat cancers driven by the RAS/MAPK pathway. The preclinical and clinical development of these pharmaceutical candidates inherently involves animal testing to satisfy regulatory requirements for safety and efficacy. The company's public filings acknowledge this standard industry practice, noting that animal rights groups have attempted to stop such testing activities through legislation and regulation. As a biotechnology firm whose mission is to "erase cancer," Erasca's research pipeline is dependent on data from animal studies to advance its drug candidates, such as ERAS-801 for malignant glioma, through the FDA approval process.
Research Sources
6 organizations
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.